文献速递免疫规划传染病防控与疫情报告

COVAIL试验中基于奥密克戎BA.1的加强mRNA疫苗与原型株疫苗对COVID-19发病率的影响比较

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.
PubMed 文献 · Vaccine · 2025-09-09

COVAIL为四阶段2期临床试验,本文报告第1阶段(mRNA-1273)和第2阶段(BNT162b2)结果:既往接种基础免疫和一剂加强针的成人随机接受第二剂原型株或奥密克戎BA.1单价/二价疫苗。第1阶段两组COVID-19累积发病率无差异,第2阶段原型株组发病率更高。

要点

  • 第1阶段(mRNA-1273)原型株与奥密克戎BA.1疫苗组COVID-19累积发病率无差异(RR 1.04)。
  • 第2阶段(BNT162b2)原型株组COVID-19发病率高于奥密克戎BA.1疫苗组(RR 2.56)。
  • 作者认为第2阶段中奥密克戎BA.1疫苗作为第二剂加强针对COVID-19的保护优于原型株疫苗。

核心结论

  • 在BNT162b2接种者中,奥密克戎BA.1疫苗作为第二剂加强针对COVID-19的保护优于原型株疫苗,而在mRNA-1273接种者中未观察到该差异。
  • 作者认为阶段间差异如感染压力、抗原匹配和疫苗差异可能解释该发现。

研究设计与样本

  • COVAIL为四阶段2期临床试验,本文描述第1阶段(mRNA-1273)和第2阶段(BNT162b2)结果。
  • 纳入已接种基础免疫和一剂已授权COVID-19疫苗加强针的成人,随机接受一剂原型株疫苗或奥密克戎BA.1单价或二价疫苗。
  • 706名有接种前和接种后第15天ID50滴度的参与者纳入分析(第1阶段n=503,第2阶段n=203)。

主要发现

  • 第1阶段原型株组与奥密克戎BA.1疫苗组COVID-19累积发病率无差异(RR 1.04,95%CI 0.73-1.48)。
  • 第2阶段原型株组COVID-19累积发病率高于奥密克戎BA.1疫苗组(RR 2.56,95%CI 1.44-4.52)。
  • Cox回归分析第1阶段无差异(HR 1.04,95%CI 0.68-1.58),第2阶段原型株组发病率更高(HR 2.95,95%CI 1.52-5.72)。
  • 各阶段内原型株组与奥密克戎BA.1疫苗组参与者的特征和基线ID50滴度相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Covid-19 vaccines are updated to match circulating strains based on reasoning that better strain-matched immunogenicity should provide better protection. Randomized evidence with disease endpoints to support strain matching is lacking. We evaluated COVID-19 incidence among adults randomized to a second booster of Prototype or Omicron-based vaccines. METHODS: COVAIL was a four-stage Phase 2 clinical trial; results from Stages 1 (mRNA-1273 [Moderna]) and 2 (BNT162b2 [Pfizer/BioNTech]) are described here. Adults who had received a primary series and one booster of an authorized COVID-19 vaccine were eligible. Participants received one dose of either Prototype vaccine or a monovalent or bivalent Omicron BA.1 vaccine. SARS-CoV-2 neutralization titers (ID50) were measured pre- and post-vaccination. Covariate-adjusted cumulative COVID-19 incidence and Cox regression analyses were conducted separately for each stage. RESULTS: 706 participants with pre- and day 15 post-vaccination ID50 titers (n = 503 in Stage 1, n = 203 in Stage 2) were included. Within stages, participant characteristics and baseline ID50 titers were similar between Prototype and Omicron-based arms. There was no difference in cumulative COVID-19 incidence for Prototype vs. Omicron-based vaccine in Stage 1 (RR 1.04, 95 % CI 0.73-1.48), while incidence was higher among Prototype recipients in Stage 2 (RR 2.56, 1.44-4.52). Cox regression analysis showed no difference in Stage 1 (HR 1.04, 0.68-1.58), but higher incidence for Prototype recipients in Stage 2 (HR 2.95, 1.52-5.72). CONCLUSIONS: Omicron-based vaccines as second boosters were more protective against COVID-19 relative to Prototype among those receiving BNT162b2 but not mRNA-1273. Differences between stages such as force of infection, antigen matching, and vaccine differences may explain this finding. CLINICALTRIALS: govRegistry Number: NCT05289037.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Diemert DJ, Graciaa DS, Zhang B, et al. Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial. Vaccine. 2025. PMID: 40930044. doi:10.1016/j.vaccine.2025.127718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。